uniQure N.V.
QURE Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$21.65
KIRA · Stoqly’s AI analyst, in plain words
- uniQure N.V. had $16.1M of revenue in fiscal 2025, down 40.6% on the year before. Over five years, revenue changed −15.6% a year on average.
- Its operating margin was −1,151.4%, down 471.8 pts: of every 100 in sales, about −1,151 is left after running the business.
- uniQure N.V. lost $199M in fiscal 2025.
- Free cash flow was −$178M in fiscal 2025, −1,108.2% of revenue.
- uniQure N.V. has $8.3M more cash than debt.
Market cap
$1.4B
P/E
—
Revenue
$16.1M
Net income
−$199M
Free cash flow
−$178M
Operating margin
−1,151.4%
uniQure N.V. in 30 seconds · fiscal 2025
Are sales growing?
−40.6%
No. Sales fell 40.6% last year.
Does it make a profit?
−1,236.0%
No. It lost money last year.
Does profit turn into cash?
−1,108.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What uniQure N.V. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- uniQure N.V.
- CIK
- 0001590560
uniQure N.V. · QURE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $524M | $106M | $15.8M | $27.1M | $16.1M |
| Revenue growth | 1,296.8% | −79.7% | −85.1% | 71.2% | −40.6% |
| Gross margin | 95.2% | 98.8% | 99.6% | 95.3% | 89.5% |
| Operating margin | 59.3% | −134.4% | −1,785.5% | −679.6% | −1,151.4% |
| Net income | $330M | −$127M | −$308M | −$240M | −$199M |
| Net margin | 62.9% | −119.1% | −1,947.1% | −883.4% | −1,236.0% |
| Diluted EPS | $7.04 | −$2.71 | −$6.47 | −$4.92 | −$3.46 |
| Cash | |||||
| Cash from operations | $288M | −$145M | −$146M | −$183M | −$178M |
| Capital expenditure | $17.4M | $17.7M | $7.2M | $3.4M | $0.4M |
| Free cash flow | $271M | −$163M | −$153M | −$186M | −$178M |
| FCF margin | 51.6% | −152.8% | −966.3% | −686.2% | −1,108.2% |
| Share count change | 5.3% | −0.2% | 2.0% | 2.1% | 18.2% |
| Debt and strength | |||||
| Cash and short-term investments | $556M | $228M | $241M | $159M | $80.2M |
| Debt incl. finance leases | $136M | $144M | $148M | $66.0M | $71.9M |
| Shareholders' equity | $596M | $476M | $208M | −$6.8M | $199M |
| Net debt / EBITDA | −1.3x | — | — | — | — |
| Current ratio | 17.1x | 6.3x | 8.8x | 9.7x | 10.4x |
| Interest coverage | 41.6x | −12.2x | −6.8x | −2.9x | −3.0x |
| Returns and quality | |||||
| Return on capital | 175.7% | −28.8% | −196.2% | — | −76.8% |
| Return on equity | 78.5% | −23.7% | −90.2% | −238.5% | −207.1% |
| Return on tangible equity | 65.2% | −32.4% | −255.3% | — | −197.5% |
| Piotroski F-score | 6 | 2 | 4 | 4 | 4 |
| Altman Z'' | 8.5 | 1.9 | −0.9 | −4.7 | −1.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$22.1M
12 insiders
Of sales under plans
90%
$19.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
uniQure N.V. · QURE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $21.65 a share, the company is worth $1.4B.
Source: SEC EDGAR XBRL filings (CIK 0001590560). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.